- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00268762
Argatroban Stroke Treatment - A Pilot Safety Study
November 3, 2014 updated by: Andrew Barreto, The University of Texas Health Science Center, Houston
A Pilot Study To Determine The Safety Of Argatroban Injection In Combination With Tissue Plasmingen Activator (TPA) In Patients With Acute Ischemic Stroke
Is the combination of low doses of argatroban in combination with rt-PA safe, and does it increase recanalization in patients with acute ischemic stroke.
Study Overview
Detailed Description
All patients with acute ischemic stroke who qualify for IV rt-PA under accepted guidelines, and who have an occluded middle cerebral artery documented on TCD, receive standard dose IV rt-PA and a bolus and 48 hour infusion of argatroban aimed at prolonging the aPTT 1.75 X baseline.
Follow up CT scanning and TCD every 30 minutes for 2 hours and then daily will determine the incidence of hemorrhage, recanalization and reocclusion, and serial neurological exam will determine the clinical outcome.
For patients without temporal windows, a baseline CT-Angiogram (CTA) demonstrating arterial occlusion can also be enrolled.
In those patients, a follow-up CTA (24-36 hours) will be performed.
Study Type
Interventional
Enrollment (Actual)
65
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- University of Alabama-Birmingham
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas-Southwestern Dallas
-
Houston, Texas, United States, 77074
- Memorial Hermann Southwest Hospital
-
Houston, Texas, United States, 77030
- Memorial Hermann Hospital-Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Ischemic stroke symptoms with onset ≤ 3 hours*.
- *or<4.5 hours according to local standard of care. Symptoms must be distinguished from another ischemic event such as syncope, seizure, migraine, and hypoglycemia. If the patient reports awakening with the event, the time of onset should be considered as last time the patient (or a witness to the patient's condition) considered herself/himself normal.
- 18-85 years of age.
- A clot causing complete or partial occlusion (TIBI 0, 1, 2, or 3) via TCD in any one of the following areas: distal iternal carotid artery (ICA), Meddle cerebral artery (MCA - M1 or M2), posterior cerebral arteral (ICA - P1 or P2), distal vertebral or basilar occlusions. TCD must be abnormal prior to the start of Argatroban. For patients without temporal windows (or in centers without emergent access to TCD), an abnormal CTA is required for enrollment (TIMI 0 or 1).
- Females of childbearing potential must have a negative serum pregnancy test prior administration of argatroban.
- Signed informed consent by the patient or the patient's legal representative.
- Meet criteria for rt-PA therapy.
Exclusion Criteria:
- Evidence of intracranial hemorrhage on baseline CT scan or non-vascular cause of neurologic deficit.
- National institute health stroke scale (NIHSS) Level of Consciousness score ≥2.
- Baseline (immediately pre-Argatroban) NIHSS ≤ 5 or patient with rapidly resolving deficit or rapidly improving symptoms consistent with TPA.
- Baseline NIHSS ≥15 for right hemisphere strokes and ≥20 for left hemisphere strokes.
- Pre-existing disability with modified rankin scale (mRS) ≥ 2.
- CT scan findings of hypoattenuation of the x-ray signal (hypodensity)involving ≥ 1/2 of the MCA territory.
- Any evidence of clinically significant bleeding, or known coagulopathy.
- Patients currently on warfarin, with an elevated INR ≥ 1.5.
- Patients currently or within previous 48 hrs. on heparin with an elevated aPTT greater than the upper limit of normal.
- Heparin flush required for an IV line. Line flushes with saline only.
- History of ICH or significant bleeding episode within the 3 months before study enrollment.
- Major surgery or serious trauma within the last 6 weeks.
- Patients who have had an arterial puncture at a non-compressible site, biopsy of parenchymal organ, or lumbar puncture within the last 2 weeks.
- Previous stroke, myocardial infarction, post myocardial infarction pericarditis, intracranial surgery, or significant head trauma within 3 months of baseline.
- Uncontrolled hypertension.
- Alcohol and/or substance abuse that would increase the risk of hemorrhage in the opinion of the investigator.
- Surgical intervention anticipated within the next 7 days.
- Hepatic dysfunction, defined by liver function tests greater than 3 times upper limit of normal at baseline, specifically serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT).
- Abnormal blood glucose
- History of primary or metastatic brain tumor.
- Severe mental deficit prior to onset of stroke such as organic brain disorder, schizophrenia, etc.
- Concurrent severe neurologic disorder, such as seizure at onset of stroke or uncontrolled seizure disorder that complicates diagnosis of acute ischemic stroke.
- Current platelet count< 100,000/mm3.
- Life expectancy <3 months in the opinion of the investigator.
- Need to be on concomitant (i.e, during the Argatroban infusion) anticoagulants other than Argatroban, including any form of heparin, unfractionated heparin (UFH), low molecular weight heparin (LMWH), defibrinogenating agent, dextran, other direct thrombin inhibitors or thrombolytic agents, glycoprotein llb/llla (GPIIb/IIIa) or warfarin.(Caveat: If these anticoagulants can be deferred for 48 hours, then they can be included).
- Participated in investigational study within 30 days before the first dose of study medication.
- Hypersensitivity to Argatroban or its agents
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Argatroban IV Infusion 1 mcg/kg/min for 48 hours
|
Argatroban IV Infusion at 1mcg/kg/min for 48 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptomatic and Radiographic Intracerebral Hemorrhage
Time Frame: Within 7 days of enrollment
|
Significant intracerebral hemorrhage as defined by either:
|
Within 7 days of enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Arterial Complete Recanalization at 2 Hours Post tPA Bolus
Time Frame: 2 hours complete recanalization post tPA bolus
|
Complete Recanalization as measured by either transcranial Doppler Ultrasound at 2 hours post tPA bolus.
|
2 hours complete recanalization post tPA bolus
|
Arterial Complete Recanalization at 24 Hours Post tPA Bolus
Time Frame: 24 hours from tPA bolus
|
Complete recanalization at 24 hours post tPA bolus as measured by either transcranial Doppler ultrasound or CT-Angiography.
|
24 hours from tPA bolus
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Andrew D. Barreto, MD, The University of Texas Health Science Center, Houston
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Sugg RM, Pary JK, Uchino K, Baraniuk S, Shaltoni HM, Gonzales NR, Mikulik R, Garami Z, Shaw SG, Matherne DE, Moye LA, Alexandrov AV, Grotta JC. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol. 2006 Aug;63(8):1057-62. doi: 10.1001/archneur.63.8.1057.
- Barreto AD, Alexandrov AV, Lyden P, Lee J, Martin-Schild S, Shen L, Wu TC, Sisson A, Pandurengan R, Chen Z, Rahbar MH, Balucani C, Barlinn K, Sugg RM, Garami Z, Tsivgoulis G, Gonzales NR, Savitz SI, Mikulik R, Demchuk AM, Grotta JC. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke. 2012 Mar;43(3):770-5. doi: 10.1161/STROKEAHA.111.625574. Epub 2012 Jan 5.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2003
Primary Completion (Actual)
August 1, 2010
Study Completion (Actual)
August 1, 2010
Study Registration Dates
First Submitted
December 20, 2005
First Submitted That Met QC Criteria
December 20, 2005
First Posted (Estimate)
December 22, 2005
Study Record Updates
Last Update Posted (Estimate)
November 10, 2014
Last Update Submitted That Met QC Criteria
November 3, 2014
Last Verified
November 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Stroke
- Ischemic Stroke
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Protease Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Argatroban
Other Study ID Numbers
- Argatroban+TPA 02-121B
- P50NS44227 project #2 (Other Grant/Funding Number: P50NS44227)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on argatroban
-
Andrew D. Barreto, MDThe University of Texas Health Science Center, HoustonTerminatedIschemic StrokeUnited States
-
Ministry of Health, Labour and Welfare, JapanMitsubishi Tanabe Pharma CorporationCompletedHeparin-Induced ThrombocytopeniaJapan
-
Mitsubishi Tanabe Pharma CorporationCompletedHeparin-induced Thrombocytopenia Type IIFrance
-
University Hospital OstravaCompleted
-
Massachusetts General HospitalGlaxoSmithKlineTerminatedCoronary Artery Bypass Graft Surgery | Presence of Heparin/Platelet Factor 4 AntibodyUnited States
-
General Hospital of Shenyang Military RegionCompletedStroke, IschemicChina
-
Canyon Pharmaceuticals, Inc.TerminatedSuspected Heparin-Induced ThrombocytopeniaUnited States
-
Hui-Sheng ChenTerminated
-
Methodist HealthcareUniversity of TennesseeWithdrawnHeparin-Induced Thrombocytopenia
-
Universitaire Ziekenhuizen KU LeuvenCompletedStaphylococcus Aureus BacteraemiaBelgium